The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies

Acute kidney injury leading to CKD is associated with a persistence of metabolic dysfunction and hypertriglyceridemia

(2021) Azadeh Harzandi et al.   iScience

Alport syndrome: Proteomic analysis identifies early molecular pathway alterations in Col4a3 knock out mice

(2020) Orthodoxia Nicolaou et al.   NEPHROLOGY

Rate of Correction of Hypernatremia and Health Outcomes in Critically Ill Patients

(2019) Kinsuk Chauhan et al.   Clinical Journal of the American Society of Nephrology

Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia

(2019) Kerim Esenboga et al.   Advances in Clinical and Experimental Medicine

A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury

(2019) Michael F. La Fountaine et al.   Scientific Reports

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

(2018) Hidenori Arai et al.   Journal of Atherosclerosis and Thrombosis

Randomized Placebo‐Controlled Trial Assessing the Effect of 24‐Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME‐2 Trial

(2018) Jenna L. Pinchbeck et al.   Journal of the American Heart Association

Lipid management in patients with chronic kidney disease

(2018) Charles J. Ferro et al.   Nature Reviews Nephrology

Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus

(2018) Takashi Yamaguchi et al.   Journal of Atherosclerosis and Thrombosis

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial

(2017) Charlotte Koopal et al.   JOURNAL OF LIPID RESEARCH

Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

(2016) Nathan R. Hill et al.   PLoS One

Chronic Kidney Disease

(2015) Paul Drawz et al.   ANNALS OF INTERNAL MEDICINE

New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies

(2015) Christelle Foucher et al.   Cardiovascular Therapeutics

The potential for renoprotection with incretin-based drugs

(2014) Tetsuhiro Tanaka et al.   KIDNEY INTERNATIONAL

A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease

(2013) Debra L. Weinstein et al.   CLINICAL THERAPEUTICS

The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome

(2013) Xiang-ping Li et al.   Lipids in Health and Disease

Meta-Analysis of Safety of the Coadministration of Statin With Fenofibrate in Patients With Combined Hyperlipidemia

(2012) Jinrui Guo et al.   AMERICAN JOURNAL OF CARDIOLOGY

Non-lipid effects of rosuvastatin–fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia

(2012) Sang-Hak Lee et al.   ATHEROSCLEROSIS

Effects of Fibrates in Kidney Disease

(2012) Min Jun et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study

(2011) R.-D. Ting et al.   DIABETES CARE

High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα–FoxO3a–PGC-1α pathway

(2011) Hyun Wha Chung et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study

(2010) Michael H. Davidson et al.   CLINICAL THERAPEUTICS

Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients

(2010) D. C. Chan et al.   DIABETES OBESITY & METABOLISM

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

(2010) T. M. E. Davis et al.   DIABETOLOGIA

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients

(2009) Giuseppe Derosa et al.   CURRENT MEDICAL RESEARCH AND OPINION

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study

(2008) Syed M. Mohiuddin et al.   AMERICAN HEART JOURNAL

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

(2008) Jean-Claude Ansquer et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study

(2008) Peter H. Jones et al.   ATHEROSCLEROSIS